CRISPR Therapeutics financials at a glance

+ Portfolio

The revenue of CRISPR Therapeutics is reported as 0.37121 billion Dollars in the fiscal year 2023. The earnings were -1.94 Dollars per share in 2023, which was 76.79 higher than 2022. And about -0.26985 billion Dollars are reported as free cash flow in the financials of CRISPR Therapeutics 2023. No dividends were paid to the shareholders of the CRISPR Therapeutics stock NasdaqGM:CRSP in the financial year 2023.

$371.21M

Revenue

$-1.94

Earnings Per Share

-39.43%

Gross Margin %

$-,225.56M

Free Cash Flow

Revenue

371.21

Earnings Per Share

-1.94

Gross Margin %

-39.43

Free Cash Flow

-,225.56

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2016	2015
Rev.	Revenue	N/A	$371.21M	$1.20M	$914.96M	$0.72M	$289.59M	$3.12M	$41.00M	$5.16M	$0.00M
GM %	Gross Margin %	-,201.65%	-39.43%	0.00%	51.72%	0.00%	38.06%	0.00%	-70.26%	0.00%	0.00%
OM	Operating Margin	-,249.20%	-59.95%	0.00%	40.82%	0.00%	16.14%	0.00%	-,157.69%	0.00%	0.00%
EPS	Earnings Per Share	$-4.48	$-1.94	$-8.36	$4.97	$-5.29	$1.17	$-3.44	$-1.71	$-6.39	$-4.20
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	0.00%	-0.00%	0.00%	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	80.28M	78.65M	77.07M	75.43M	60.85M	52.28M	46.98M	39.81M	5.53M
OCF	Operating Cash Flow	N/A	$-,260.38M	$-,495.74M	$538.97M	$-,238.37M	$0.00M	$-96.24M	$0.00M	$-55.31M	$0.00M
FCF	Free Cash Flow	N/A	$-,225.56M	$-,532.93M	$457.27M	$-,256.72M	$0.00M	$-99.01M	$0.00M	$-58.33M	$0.00M
FCFS	Free Cash Flow Per Share	$-3.74	$-3.44	$-6.85	$6.02	$-3.89	$0.92	$-2.06	$-1.94	$-1.70	$0.00

CRISPR Therapeutics financials at a glance

Financials

Discover